文献速递核素与放射性配体治疗

α发射体与β发射体用于癌胚抗原表达人结肠癌异种移植瘤预靶向放射免疫治疗的比较

α- Versus β-Emitting Radionuclides for Pretargeted Radioimmunotherapy of Carcinoembryonic Antigen-Expressing Human Colon Cancer Xenografts.
PubMed 文献 · J Nucl Med · 2017-02-23

研究在LS174T结肠癌荷瘤小鼠中比较了α发射体213Bi-IMP288与β发射体177Lu-IMP288经TF2双特异性抗体预靶向后的肿瘤靶向性与疗效。213Bi-IMP288体外结合特性与177Lu-IMP288相似,单次给药后两者均显著抑制肿瘤生长,中位生存期分别为31、45天(6、12 MBq 213Bi)与42天(60 MBq 177Lu),但较高剂量213Bi出现肾毒性。

要点

  • 213Bi-IMP288与177Lu-IMP288对TF2预靶向LS174T细胞的体外结合特性相似。
  • 单次213Bi-IMP288或177Lu-IMP288均显著抑制肿瘤生长,12 MBq 213Bi中位生存45天。
  • 17 MBq 213Bi-IMP288出现显著体重下降及肾小管损伤,提示肾毒性。

核心结论

  • 本研究首次表明TF2与213Bi-IMP288预靶向放射免疫治疗可行,且至少与177Lu-IMP288同样有效。
  • 但较高剂量下观察到肾脏毒性。
  • 未来需进一步研究以确定最佳给药方案,在提高疗效的同时减少肾毒性。

研究设计与样本

  • 研究比较了213Bi-IMP288与177Lu-IMP288的体外结合特性。
  • 在皮下LS174T肿瘤小鼠中,经TF2预靶向后研究213Bi-IMP288与177Lu-IMP288的肿瘤靶向性。
  • 评估213Bi-IMP288(6、12或17 MBq)与177Lu-IMP288(60 MBq)对肿瘤生长和生存的影响。
  • 通过监测体重、分析血液样本的血液学与肾毒性指标(血红蛋白、白细胞、血小板、肌酐)及肾脏免疫组化分析确定毒性。

主要发现

  • 213Bi-IMP288对TF2预靶向LS174T细胞的解离常数为0.45 ± 0.20 nM,177Lu-IMP288为0.53 ± 0.12 nM。
  • 注射后15分钟即可观察到213Bi-IMP288在LS174T肿瘤中的蓄积,为9.2 ± 2.0 %ID/g。
  • 注射后30分钟213Bi-IMP288血液水平为0.44 ± 0.28 %ID/g,肾脏摄取为1.8 ± 1.1 %ID/g。
  • 磷酸盐缓冲液组、6 MBq 213Bi-IMP288组、12 MBq 213Bi-IMP288组和60 MBq 177Lu-IMP288组的中位生存期分别为22、31、45和42天。
  • 接受17 MBq 213Bi-IMP288的小鼠出现显著体重下降,中位生存期仅24天;17或12 MBq 213Bi-IMP288治疗小鼠肾脏免疫组化显示肾小管损伤迹象。

关键数值与推荐

  • 213Bi-IMP288解离常数0.45 ± 0.20 nM,177Lu-IMP288解离常数0.53 ± 0.12 nM。
  • 213Bi-IMP288注射后15分钟肿瘤摄取9.2 ± 2.0 %ID/g,30分钟血液0.44 ± 0.28 %ID/g、肾脏1.8 ± 1.1 %ID/g。
  • 中位生存期:磷酸盐缓冲液组22天,6 MBq 213Bi-IMP288组31天,12 MBq 213Bi-IMP288组45天,60 MBq 177Lu-IMP288组42天,17 MBq 213Bi-IMP288组24天。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文指出未来需进一步研究以确定最佳给药方案,在提高疗效的同时减少肾毒性。
  • 较高剂量213Bi-IMP288下观察到肾脏毒性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Pretargeted radioimmunotherapy (PRIT) with the β-emitting radionuclide 177Lu is an attractive approach to treat carcinoembryonic antigen (CEA)-expressing tumors. The therapeutic efficacy of PRIT might be improved using α-emitting radionuclides such as 213Bi. Herein, we report and compare the tumor-targeting properties and therapeutic efficacy of 213Bi and 177Lu for PRIT of CEA-expressing xenografts, using the bispecific monoclonal antibody TF2 (anti-CEA × anti-histamine-succinyl-glycine [HSG]) and the di-HSG-DOTA peptide IMP288. Methods: The in vitro binding characteristics of 213Bi-IMP288 were compared with those of 177Lu-IMP288. Tumor targeting of 213Bi-IMP288 and 177Lu-IMP288 was studied in mice bearing subcutaneous LS174T tumors that were pretargeted with TF2. Finally, the effect of 213Bi-IMP288 (6, 12, or 17 MBq) and 177Lu-IMP288 (60 MBq) on tumor growth and survival was assessed. Toxicity was determined by monitoring body weight, analyzing blood samples for hematologic and renal toxicity (hemoglobin, leukocytes, platelets, creatinine), and immunohistochemical analysis of the kidneys. Results: The in vitro binding characteristics of 213Bi-IMP288 (dissociation constant, 0.45 ± 0.20 nM) to TF2-pretargeted LS174T cells were similar to those of 177Lu-IMP288 (dissociation constant, 0.53 ± 0.12 nM). In vivo accumulation of 213Bi-IMP288 in LS174T tumors was observed as early as 15 min after injection (9.2 ± 2.0 percentage injected dose [%ID]/g). 213Bi-IMP288 cleared rapidly from the circulation; at 30 min after injection, the blood levels were 0.44 ± 0.28 %ID/g. Uptake in normal tissues was low, except for the kidneys, where uptake was 1.8 ± 1.1 %ID/g at 30 min after injection. The biodistribution of 213Bi-IMP288 was comparable to that of 177Lu-IMP288. Mice treated with a single dose of 213Bi-IMP288 or 177Lu-IMP288 showed significant inhibition of tumor growth. Median survival for the groups treated with phosphate-buffered saline, 6 MBq 213Bi-IMP288, 12 MBq 213Bi-IMP288, and 60 MBq 177Lu-IMP288 was 22, 31, 45, and 42 d, respectively. Mice receiving 17 MBq 213Bi-IMP288 showed significant weight loss, resulting in a median survival of only 24 d. No changes in hemoglobin, platelets, or leukocytes were observed in the treatment groups. However, immunohistochemical analysis of the kidneys of mice treated with 17 or 12 MBq 213Bi-IMP288 showed signs of tubular damage, indicating nephrotoxicity. Conclusion: To our knowledge, this study shows for the first time that PRIT with TF2 and 213Bi-IMP288 is feasible and at least as effective as 177Lu-IMP288. However, at higher doses, kidney toxicity was observed. Future studies are warranted to determine the optimal dosing schedule to improve therapeutic efficacy while reducing renal toxicity.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Heskamp S, Hernandez R, Molkenboer-Kuenen JDM, et al. α- Versus β-Emitting Radionuclides for Pretargeted Radioimmunotherapy of Carcinoembryonic Antigen-Expressing Human Colon Cancer Xenografts. J Nucl Med. 2017. PMID: 28232604. doi:10.2967/jnumed.116.187021

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。